SCHEMBL7174883

SCHEMBL7174883

CCCCOc1ccc(PC(=O)c2c(OC)cccc2OC)c(OCCCC)c1.[LiH]

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.42
THRA P10827 1/20 0.42
PPARA Q07869 2/20 0.41
PPARG P37231 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
FAAH O00519 1/20 0.39
MAPT P10636 3/20 0.39
LMNA P02545 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7175103 0.98 THRB (0.46) THRBTHRAPPARAMAPTLMNA
Lithium SCHEMBL7174887 0.98 THRB (0.42) THRBTHRAPPARAPPARGSMN1; SMN2
SCHEMBL7181178 0.97 THRA (0.47) THRBTHRAPPARA
SCHEMBL7180946 0.95 KMT2A (0.42) THRBTHRASMN1; SMN2KMT2ACA12
SCHEMBL7181770 0.93 MEN1 (0.42) THRBTHRAPPARAPPARGSMN1; SMN2
Lithium SCHEMBL7180963 0.93 KMT2A (0.42) THRBTHRASMN1; SMN2KMT2ACA12
SCHEMBL7187096 0.92 THRA (0.43) THRBTHRASMN1; SMN2MEN1GAA
SCHEMBL7180980 0.91 THRA (0.43) THRBTHRAPPARAMEN1GAA
Lithium SCHEMBL7181773 0.91 MEN1 (0.42) THRBTHRAPPARAPPARGSMN1; SMN2
SCHEMBL7184610 0.91 MAPT (0.41) SMN1; SMN2MEN1KMT2ACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 THRB 2119/4885THRA 1901/4885PPARA 3039/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 THRB 2521/4885THRA 2159/4885PPARA 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.